Bristol-Myers Squibb Company (BMY) earnings on July 30, 2026

Before the market opens Q2 2026

More Bristol-Myers Squibb Company earnings

Prior outlook: Optimistic Outcome: Accurate

Bristol-Myers Squibb beat profit estimates and raised its outlook, lifting the stock price.

BMY price around the earnings

64.86

Change: +2.8%

2026-07-30, 20:00 UTC

Start of the measured window End of the measured window
62.21 63.32 64.44 65.55 63.10
Price series around the eventClosing price per minute from before the event to the end of the measured window.
July 30, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • Start of the measured window
  • End of the measured window
  • Market open
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Optimistic Outcome: Accurate

Thesis published
Results released

Strong historical earnings beats and positive trend strength, but analyst upside is minimal with mixed market sentiment.

Context analyzed before publication

Trend
Positive trend strength into event, but recent trajectory shows a sharp decline on the last day.

Analysts

Evidence

Analyst consensus
Buy
Consensus average (1-5)
2.5
Analysts covering the stock
24
Average price target
62.96
Lowest price target
40
Highest price target
75
Upside to price target
-0.2%
Quarterly earnings growth
9%
Revenue growth
2.6%
Forward EPS
6.19
Trailing EPS
3.54
Analyst moves in the last 60 days
2
  • Strong buy: 4
  • Buy: 6
  • Hold: 17
  • Sell: 1
  • Strong sell: 0
Strong buy
4
Buy
6
Hold
17
Sell
1
Strong sell
0
  • July 10, 2026 · B of A Securities: Maintains rating (Buy → Buy)
  • July 6, 2026 · Cantor Fitzgerald: Reiterates rating (Neutral → Neutral)

News and sentiment

Evidence

Sentiment
Sentiment
Constructive
Mention volume
Low
Normalized volume
33%
News
Sources (5)

Technicals

Evidence

Price when the context was analyzed
63.11
Average true range (ATR)
2.4%
Distance to 52-week high
-0.8%
14-day change (14d)
+7.5%
30-day change (30d)
+7.8%
30-day relative strength
+9.3%
SPY change (30d)
-1.5%
Nearest support
62.84
Distance to nearest support
0.4%
Nearest resistance
63.12
Distance to nearest resistance
0%
Volume accumulation ratio (14d / 46d)
1
  • Mid: 62.84 (0.4% away, 0.18 ATR, 6 touches)
  • Mid: 62.57 (0.9% away, 0.37 ATR, 8 touches)
  • Minor: 62.07 (1.7% away, 0.7 ATR, 6 touches)
  • Mid: 63.12 (0% away, 0.01 ATR, 8 touches)
  • Minor: 63.47 (0.6% away, 0.24 ATR, 3 touches)
  • Minor: 63.94 (1.3% away, 0.56 ATR, 2 touches)

Trends

Evidence

Average earnings surprise
+14.0%
  • April 30, 2026: actual EPS 1.58 vs estimate 1.42 (surprise +11.2%)
  • February 5, 2026: actual EPS 1.26 vs estimate 1.2 (surprise +4.6%)
  • October 30, 2025: actual EPS 1.63 vs estimate 1.52 (surprise +7.5%)
  • July 31, 2025: actual EPS 1.46 vs estimate 1.1 (surprise +32.6%)

Expected move

Implied move
+4.8%
Source
Options chain

Reactions over its last 20 earnings

Median move
3.1%
75th percentile move
5.8%
90th percentile move
7.2%
Up / down moves
11 / 9
Average up move
+3.9%
Average down move
-3.9%

Monitoring and close

What Bristol-Myers Squibb Company reported

Status
Finished
Actual EPS2.04
EPS estimate1.59
EPS surprise+28.3%
Revenue$12,973 million
Revenue estimate$11,745 million
Revenue surprise+10.5%

Bristol-Myers Squibb beats Q2 estimates and raises 2026 guidance, driven by growth drugs. Optimistic outlook.

Sources (24)

Pre-market second reading after the results

Verdict
Beat expectations

Heading into the open, results beat expectations on both earnings and revenue and the price is indicating +1.1% pre-market, a move below the stock's usual reaction (about 3%). The figures confirm the optimistic scenario. Across our market history, in the 1,580 similar cases the close held that direction 75% of the time.

How the stock reacted

Outcome
Accurate
Consolidated
+2.8%
Max favorable move (MFE)
3.9%
Max adverse move (MAE)
1.4%